Empowered Funds LLC Takes $5.68 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Empowered Funds LLC bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, HoldingsChannel reports. The firm bought 331,209 shares of the biotechnology company’s stock, valued at approximately $5,680,000.

Other institutional investors also recently bought and sold shares of the company. State Street Corp boosted its holdings in shares of ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after purchasing an additional 4,945,063 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after buying an additional 137,989 shares in the last quarter. Perpetual Ltd purchased a new stake in shares of ADMA Biologics in the fourth quarter worth about $62,300,000. Assenagon Asset Management S.A. boosted its stake in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in ADMA Biologics during the 3rd quarter valued at approximately $61,858,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the topic of several recent research reports. HC Wainwright upped their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James upped their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Trading Down 4.7 %

Shares of ADMA stock opened at $15.88 on Wednesday. The company has a market cap of $3.75 billion, a PE ratio of 56.71 and a beta of 0.75. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64. The stock’s 50 day simple moving average is $17.58 and its two-hundred day simple moving average is $17.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Insider Activity

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.